Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth.
about
Cellular and humoral immunodepression in vultures feeding upon medicated livestock carrionHuman microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approachesMethicillin-resistant Staphylococcus aureus phage plaque size enhancement using sublethal concentrations of antibioticsSynergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureusThree New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage TherapyThe use of antibiotics to improve phage detection and enumeration by the double-layer agar technique.Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.Taking bacteriophage therapy seriously: a moral argumentGene network visualization and quantitative synteny analysis of more than 300 marine T4-like phage scaffolds from the GOS metagenome.Antibiotics in feed induce prophages in swine fecal microbiomesFinding alternatives to antibiotics.Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections.P1 Ref Endonuclease: A Molecular Mechanism for Phage-Enhanced Antibiotic Lethality.In Vivo Assessment of Phage and Linezolid Based Implant Coatings for Treatment of Methicillin Resistant S. aureus (MRSA) Mediated Orthopaedic Device Related Infections.Parasites and competitors suppress bacterial pathogen synergistically due to evolutionary trade-offs.Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophagesAntibiotic resistance shaping multi-level population biology of bacteria.Extracellular protease digestion to evaluate membrane protein cell surface localization.Simple method for plating Escherichia coli bacteriophages forming very small plaques or no plaques under standard conditionsDecreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problemsCharacterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog® system.Modification of Escherichia coli-bacteriophage interactions by surfactants and antibiotics in vitro.Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.Bacteriophage based probes for pathogen detection.Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.Phage approved in food, why not as a therapeutic?The minor groove-binding agent ELB-21 forms multiple interstrand and intrastrand covalent cross-links with duplex DNA and displays potent bactericidal activity against methicillin-resistant Staphylococcus aureus.Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing.Biofilm control with natural and genetically-modified phages.Predation and selection for antibiotic resistance in natural environments.Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models.Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives.Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa.[Phage therapy: a realistic weapon against multidrug resistant bacteria].Listeria phage and phage tail induction triggered by components of bacterial growth media (phosphate, LiCl, nalidixic acid, and acriflavine).Host range and in vitro lysis of Listeria monocytogenes seafood isolates by bacteriophages.
P2860
Q24649947-C667DD39-DDF3-4194-9BFC-82A91FE5CBD9Q26779242-5EB01131-915B-4F00-8FCD-231207A29325Q28390950-A20D4C44-4CCF-4D33-8EAE-DB0A31C12841Q28485429-7397CE2C-D0BC-4159-A214-07C454799CBCQ28550170-0605F8E9-8E79-4A38-82C4-FF849BFF9DBCQ33486138-5D3AFD64-32BB-4FE3-BC3C-8D92604A8787Q33553795-194913AC-F60A-4E37-92D6-93F44E300ACFQ33608714-879B8B2C-F32A-4D7D-95E0-A1B4DDE25417Q34014432-1F06FFBF-226A-4D84-A7C9-F40A7857BCE2Q34086534-D2A423B3-76C5-44C4-B0A3-645FD3EB3E0AQ34426004-E2B3AFE5-D4E4-4860-841A-80F753B9FFC5Q34426663-78E093A1-CA58-40F4-9EDC-9332D12B75B5Q34594381-2221DFBB-AA61-46D4-82DC-971B41832DF4Q34933915-7756C5E9-7646-4BF1-A3F4-08884A925708Q35154348-7820EF91-FF83-4FDC-BA5C-CCFD70558494Q35893892-07682411-0610-47A6-B229-227EC95B1D85Q36059113-87910824-25F4-487C-8668-0288A346A8CEQ36214728-36242836-253E-43DD-904C-860837D03918Q36396094-8A4C05B2-39BA-4C3F-BB4F-50552C1F53BCQ36660833-B79E509C-2647-4D0B-81E4-0CC4927A3AF0Q36817556-D1061060-1C5E-4CB9-9622-E10E27C146EBQ36844815-10C23522-3D46-45E7-8BA7-920E53B75B9FQ37273419-9D50888A-EB18-46F7-932B-D2E1C8ACF699Q37324738-53FB63B2-7A72-4E73-A74D-3920C7482286Q37387916-4AFEC89E-4ADE-401C-AC8E-32BFAE8D35B5Q37929756-097AC95F-8001-49A1-B7C7-BC3B7BE1093FQ38020842-D757F30E-5F22-444C-80BB-2E6C51649B74Q38215724-71AD9212-0DAC-475C-B416-C01F08DD1F02Q38285489-8162ED9A-E846-433D-A0CC-1F33ECDFC816Q38336785-99ED137A-3671-4442-89AD-F32D919AB8B6Q38686917-7828AFA0-F4A3-438E-8944-09AF88EAFCB2Q38756810-43EC3B4C-534B-4087-8C60-8B667AC945EAQ38775279-2AE53666-E8ED-4975-82AD-7966E5EDB086Q39671563-29F5AE69-4851-4ECD-AD82-1F5776D85391Q39690702-60F0868E-C02C-4D7C-BA67-B4D9C1CEE1F9Q40054770-2E39A756-66D7-4C8B-8F03-41BBB0D7AA04Q40165457-EAF5B767-72F5-4954-92B8-86ACCECDFDADQ40204267-BBE88939-76E0-456C-BF1B-66487F8B0000Q42118626-D6C2B577-8D92-43C4-8148-CD58D783ACEDQ42279647-2F5C6B35-9F6E-4903-80DD-447F186D3FDA
P2860
Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@ast
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@en
type
label
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@ast
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@en
prefLabel
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@ast
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@en
P2093
P2860
P1433
P1476
Phage-Antibiotic Synergy (PAS) ...... imulate virulent phage growth.
@en
P2093
André M Comeau
Françoise Tétart
H M Krisch
Marie-Françoise Prère
Sabrina N Trojet
P2860
P356
10.1371/JOURNAL.PONE.0000799
P407
P577
2007-08-29T00:00:00Z